Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung

Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung

(2018) Ayako Hirai et al.   JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1

(2017) Yuki Ikematsu et al.   LUNG CANCER

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

(2017) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis

(2017) Violaine Yvorel et al.   PLoS One

High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma

(2016) Yih-Leong Chang et al.   EUROPEAN JOURNAL OF CANCER

PD-L1 Expression in Lung Cancer

(2016) Hui Yu et al.   Journal of Thoracic Oncology

Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma

(2016) Kazuki Takada et al.   Journal of Thoracic Oncology

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages

(2016) Thibault Vieira et al.   LUNG CANCER

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells

(2016) Y. Ohue et al.   Cancer Immunology Research

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Classifying Cancers Based on T-cell Infiltration and PD-L1

(2015) Michele W.L. Teng et al.   CANCER RESEARCH

PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma

(2015) F. Sabbatino et al.   CLINICAL CANCER RESEARCH

Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas

(2015) Sehui Kim et al.   EUROPEAN JOURNAL OF CANCER

The 2015 World Health Organization Classification of Lung Tumors

(2015) William D. Travis et al.   Journal of Thoracic Oncology

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC)

(2015) Fumihiro Tanaka et al.   SURGERY TODAY

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

(2013) M. Sznol et al.   CLINICAL CANCER RESEARCH

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1)

(2013) Vamsidhar Velcheti et al.   Journal of Thoracic Oncology

Efficacy of First-Line Chemotherapy in Patients with Advanced Lung Sarcomatoid Carcinoma

(2013) Thibault Vieira et al.   Journal of Thoracic Oncology

Programmed death ligand-1 expression in non-small cell lung cancer

(2013) Vamsidhar Velcheti et al.   LABORATORY INVESTIGATION

Clinicopathological characteristics of surgically resected pulmonary pleomorphic carcinoma

(2012) F. Chen et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine